Encore Presentation of Landmark REDUCE-IT™ Cardiovascular Outcomes Trial Featured In NLA Scientific Sessions Late-Breaking Abstract Presentation

Last Updated: Wednesday, 29-May-2019 20:15:00 EDT

An encore presentation of the landmark cardiovascular outcomes trial REDUCE-IT™ (Reduction of Cardiovascular Events With EPA - Intervention Trial) was presented as a Late-Breaking Abstract by Amarin at the National Lipid Association 2019 Scientific Sessions, taking place in Miami May 16 – 19.

The presentation on Saturday, May 18, 4:40-4:50 p.m. included the total events analysis from the REDUCE-IT study, as first presented March 2019 and published in the Journal of the American College of Cardiology.

This analysis showed that Vascepa® provided a statistically significant 30 percent risk reduction in total (first and subsequent) cardiovascular events compared to placebo in the statin-treated patient population studied in REDUCE-IT, resulting in an average of approximately one fewer major adverse cardiovascular events per six patients treated with Vascepa® compared to placebo over a five-year period.

A slide presentation is available for viewing and download here

Copyright © 2018 National Lipid Association. All Rights Reserved.

Privacy Policy Terms of Service